01 · Process stage
PlannedMolecule toxicity assessment
Evaluate the specific occupational exposure band and toxicological data for the proposed compound.
Capabilities · Specialist manufacturing domains
Highly potent & cytotoxic products
A proposed service scope for highly potent and cytotoxic formulations, connecting risk assessment, facility containment strategies and occupational exposure limits.
PlannedCatalogue scope
Service statusPlanned
Planned.
Technical boundaries and readiness need confirmation before an activity could be presented as available.
Basis · Catalogue scope
- Status
- PlannedNo available service asserted
- Source-plan relationship
- Catalogue scopeProposed catalogue expansion
- Readiness
- Not establishedProduct and process evidence needed
- Facility roadmap
- First commercial batch target Q1 2028 · indicativeNot a service date
01 · Proposed service scope
Start with the product and its container.
Handling highly potent and cytotoxic materials is presented as a planned service domain. The exact molecule, occupational exposure limit and intended presentation would define its scope.
The initial formulation-and-filling plan does not identify highly potent or cytotoxic products. The proposed catalogue adds this specialised handling category as an extension, which would require separate scope confirmation.
Cytotoxic compounding and facility segregation are distinct technical subjects. Inclusion in a common catalogue does not establish that infrastructure is appropriate for a particular molecule.
Catalogue boundary
A planned catalogue for scoped evaluation. Inclusion does not establish installed, qualified, licensed or available capability.
02 · Presentation families
Match the route to the format.
| Format | Planning note | Basis | Status |
|---|---|---|---|
| Cytotoxic active substances | Proposed category extension; requires molecule-specific toxicological evaluation for scoping. | Catalogue scope | Planned |
| Highly potent drug products | Proposed addition; demands dedicated containment and stringent operator handling protocols. | Catalogue scope | Planned |
| Occupational exposure assessments | Documentation needed to establish safe handling limits and physical boundaries. | Catalogue scope | Planned |
03 · Process scope for discussion
Make the sequence and its evidence visible.
02 · Process stage
PlannedContainment strategy definition
Define appropriate isolation, ventilation and handling controls for the intended formulation work.
03 · Process stage
PlannedFacility segregation planning
Consider the required physical boundaries, dedicated air handling and separate material flows.
04 · Process stage
PlannedOperator protection procedures
Detail gowning, respiratory protection and monitoring steps required during the proposed processing.
05 · Process stage
PlannedDeactivation and cleaning design
Determine appropriate cleaning agents, deactivation protocols and verification methods for product-contact surfaces.
06 · Process stage
PlannedWaste management protocols
Establish appropriate disposal routes for contaminated materials, primary packaging and liquid effluents.
Illustrative sequence
This is a technical discussion structure, not an operating procedure, approved process flow or representation of installed equipment.
04 · Supporting services
No service stands alone.
01PlannedCatalogue scope
Container-closure development
Compatibility, presentation and container-closure questions for the exact product.
Explore proposed scope02PlannedCatalogue scope
Small-molecule active ingredients
Proposed synthesis, isolation and purification domains; scope confirmation required.
Explore proposed scope03PlannedCatalogue scope
Process & cleaning validation support
Defined scope, protocols, acceptance criteria and evidence packages.
Explore proposed scope05 · Readiness questions
A service claim needs a defined evidence base.
- Toxicological data
- Complete safety profiles, exposure limits and specific material handling hazards.
- Facility design
- Appropriate isolation barriers, airlocks and relevant dedicated ventilation systems.
- Cleaning verification
- Appropriate validation for deactivation methods and accepted trace-level analytical detection limits.
- Handling procedures
- Accepted protocols for material transfer, routine processing and spill response.
- Regulatory permissions
- Applicable authorisations for highly potent material storage, processing and disposal.
- Technical agreement
- Documented responsibilities for safety information disclosure and dedicated contamination control.
06 · Practical questions
Before a technical discussion.
Is this service currently available?
No. The service is Planned. This page is a scope proposal and does not establish an operating highly potent or cytotoxic manufacturing service.
Are highly potent products part of the initial plan?
No. The initial Boten plan identifies specific injectable presentation families and protein raw-material production; it does not identify highly potent or cytotoxic products. This line would require separate scope confirmation.
What information helps define the question?
Identify the proposed compound, occupational exposure band, product type and the technical handling question. Confidential safety data should only be shared through an agreed route.
Is there a service launch quarter?
No. No service-specific quarter is established. The project-wide indicative milestones do not commit any individual service to a start date.
Does a technical discussion establish supply?
No. Feasibility, scope, permissions, containment evidence and any agreement would need to be established before a service or supply commitment.
Professional enquiries
Discuss a defined question.
Describe the presentation, development question and destination relevant to the proposed scope. Do not infer service availability from this planning page.